title: Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.
abstract: OBJECTIVE
  Steroid dependence and early relapse are frequent after a prednisolone-induces remission in Crohn's disease. The aim of this trial was to test whether mesalamine started at the onset of steroid tapering increases the rate of weaning from prednisolone and reduces the relapse rate after prednisolone cessation.
  
  
  METHODS
  One hundred fifty patients with active Crohn's disease were administered oral prednisolone (1 mg.kg(-1). day(-1)) x 3-7 weeks; 129 patients went into clinical remission and were randomized to Pentasa (4 g . day(-1)) or placebo, administered until weaning and for 1 year thereafter.
  
  
  RESULTS
  Groups were similar for clinical and biological items collected initially. Weaning failure rate was 30% and 12% in the placebo and mesalamine arms, respectively. At the end of the trial, 9 of 36 patients administered placebo and 14 of 48 administered mesalamine were in remission. Both groups had similar time to relapse curves in the postweaning year; after adjusting for risk factors (high Crohn's Disease Activity Index, white blood cell count of >9 x 10(9) /l-1 at weaning, and use of a medical treatment in the month before inclusion), Pentasa was found to be superior to placebo.
  
  
  CONCLUSIONS
  After a prednisolone-induces remission in Crohn's disease, mesalamine facilitates steroid withdrawal and, during the postweaning year, may reduce the relapse rate in certain patient subgroups.
authors.affiliation: Hôspital Saint-Louis, Paris, France.
authors.forename: R
authors.initials: R
authors.lastname: Modigliani
authors.forename: J F
authors.initials: JF
authors.lastname: Colombel
authors.forename: J L
authors.initials: JL
authors.lastname: Dupas
authors.forename: M
authors.initials: M
authors.lastname: Dapoigny
authors.forename: V
authors.initials: V
authors.lastname: Costil
authors.forename: M
authors.initials: M
authors.lastname: Veyrac
authors.forename: B
authors.initials: B
authors.lastname: Duclos
authors.forename: J C
authors.initials: JC
authors.lastname: Soulé
authors.forename: J P
authors.initials: JP
authors.lastname: Gendre
authors.forename: J P
authors.initials: JP
authors.lastname: Galmiche
authors.forename: O
authors.initials: O
authors.lastname: Danne
authors.forename: G
authors.initials: G
authors.lastname: Cadiot
authors.forename: H
authors.initials: H
authors.lastname: Lamouliatte
authors.forename: J
authors.initials: J
authors.lastname: Belaïche
authors.forename: J Y
authors.initials: JY
authors.lastname: Mary
mesh_terms: D000293:Adolescent; D000328:Adult; D000636:Aminosalicylic Acids / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001530:Belgium; D016009:Chi-Square Distribution; D003424:Crohn Disease / Q000188:drug therapy*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D005602:France; D006801:Humans; D016015:Logistic Models; D008297:Male; D019804:Mesalamine; D011239:Prednisolone / Q000008:administration & dosage / Q000627:therapeutic use*; D016016:Proportional Hazards Models; D012008:Recurrence; D012074:Remission Induction
chemical_list: D000636:Aminosalicylic Acids; D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D019804:Mesalamine; D011239:Prednisolone